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Background: Nutritional deficiencies are widespread in people living with HIV (PLWH), prior
to the antiretroviral treatment (ART). Nutrient deficiencies and other nutrition-related conditions,
however, have been identified in patients receiving ART. Trials of nutritional supplementation
have been conducted to alleviate these nutritional conditions and improve or reverse nutritionrelated outcomes. This review aims to evaluate the benefits of supplementation, its unintended
adverse effects, and the difference in approach and focus, research design, formulations, and
outcomes between those randomized clinical trials (RCTs) conducted before and after the
initiation of ART.
Methods: An evidence-based systematic review of the literature was conducted using electronic
databases and the resources of the Florida International University Research Library. Forty-two
RCTs were selected for review, and their design and outcomes were compared and contrasted
conceptually and in the form of tables.
Results: Most of the RCTs (n=31) were conducted before the advent of ART, and their aims
were delaying disease progression, reversing malnutrition, and improving pregnancy outcomes
in women and infants infected with HIV. The RCTs conducted with coadministration of ART
were fewer (n=11), with relative smaller sample size, of shorter duration, and mainly focused on
preventing or ameliorating the nutrition-related conditions generated by the chronic infection,
its treatment, and the aging of PLWH.
Conclusion: As ART is becoming more accessible worldwide, and people are living longer
with the disease, more longitudinal trials of nutritional interventions with larger sample sizes
are needed to study the nutritional consequences and potential treatments for PLWH.
Keywords: HIV, antiretroviral therapy, micronutrients, probiotics, AIDS, randomization,
clinical trial
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In limited-resource countries, severe malnutrition continues to be a growing problem,
and it is frequently superimposed on the ongoing HIV pandemic.1 Studies among people
living with HIV (PLWH) have found metabolic and nutritional abnormalities, which
may be either secondary to the HIV infection or due to primary malnutrition caused
by insufficient intake. Nutritional deficiencies, when present, compromise the immune
system and facilitate HIV disease progression.2 In HIV disease, immunodeficiency and
deficits in nutrition interact early in the disease, before antiretroviral treatment (ART)
is provided; however, nutritional deficits and its possible consequences have also been
observed after the disease is managed with ART.3,4 Antiretrovirals are life-saving medications that, although do not cure the disease, control its progression5,6 and improve
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nutritional status7,8 but generate new nutritional challenges.
The nutritional problems observed in patients on ART differ from those seen prior to the provision of treatment;7,9–11
therefore, the purpose and formulation of the nutritional
supplementation should also change. Different from previous
reviews of nutritional supplementation in HIV infection, this
review of randomized clinical trials (RCTs) of nutritional
supplementation in PLWH for the first time considers the
coadministration of ART and divides the review according
to whether antiretrovirals were used in the trials.
ART suppresses the HIV virus and helps in the recuperation of the immune function. However, only about one-third
of patients who achieve viral control recover protective
immunity. Poor recovery of the immune function places
these patients at increased risk of morbidity and mortality.12–14
Moreover, ART combinations containing some of the early
antiretrovirals may increase oxidative stress, mitochondrial
injury, and increase the host’s needs for antioxidants.15–20
Chronic ART has also been associated with gastrointestinal
(GI) symptoms that may decrease nutrient absorption and
metabolism.21
Several reports suggest that micronutrient supplementation may support the immune system before and during
the chronic use of ART22–25 and prevent ART-associated
mitochondrial damage.26,27 Multivitamins and minerals
are essential for supporting innate immunity, preventing
its decline and promoting a timely reconstitution of the
specific immune system. 15–18,23,28 Most of the RCTs of
nutritional supplementation reviewed by this work were
performed before the availability of ART and demonstrated
the immunostimulatory effects of micronutrients in PLWH
(Table 1).
The trials in which nutritional supplements were coadministered with ART are few (Tables 2 and 3), with a limited
sample size and duration of supplementation. The lack of
emphasis on nutritional supplementation after the advent
of ART might be due to expectations that treatment with
antiretrovirals would have reversed nutritional and metabolic
alterations. The interpretation of the findings of RCTs in
which nutritional supplements were coadministered with
ART is complex. ART combinations are multiple, and the
selection of the combination for a given patient depends on
the genetics of the host and virus, the degree of resistance
to certain antiretrovirals, and personal and national socioeconomic conditions.
This review highlights the benefits of nutritional supplementation before ART is initiated and the scarcity of sufficiently powered RCTs that evaluate the impact of nutritional
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supplementation during ART on immune recovery, morbidity,
and mortality in PLWH.

Background
The literature indicates that nutritional deficiencies are
widespread in PLWH, which are manifested early in the
infection, before clinical symptoms are present, and prior
to initiating ART.28–38 Although the use of ART has been
shown to reduce wasting, the condition is still prevalent
among patients receiving ART.10 In the era of ART, wasting
is more frequently observed in cases with virologic and/or
immunological failure, who are living in poor socioeconomic
conditions and with high food insecurity.10,39 Micronutrient
deficiencies have also been observed, even in patients receiving chronic ART. Jones et al40 reported a high prevalence of
zinc deficiency in participants on ART, adjusting for parameters of acute-phase reaction.
The continuous struggle of the immune system to control
HIV may produce a hypermetabolic state, which is associated
with increased caloric expenses, high rates of fat oxidation,41
and rapid depletion of essential micronutrients.29 Therefore,
adequate nutritional intake is critical for PLWH, particularly
before initiation of ART, to offset the increased nutritional
needs for calories and proteins produced by competition for
these nutrients with the virus and the demands placed by a
continuously activated immune system. The development
of combined ART brought expectations that, once the virus
was under control, the immune system would recover, the
increased nutritional demands would diminish, and nutritional disturbances would be reversed.
Depletion of memory T-cells in the GI mucosa is the
consequence of symptoms of diarrhea and malnutrition
caused by HIV, which in turn causes bacterial translocation,
which furthers immune activation, inflammation and oxidative stress, contributing to HIV progression.42–44 Other GI
manifestations observed in the pre-ART era were chronic
enteropathy and altered GI integrity.45,46
ART, however, has also affected GI integrity; patients
receiving ART have complications related to colitis associated with antimicrobial medications, side effects of ART,47
and changes in microbiota.48 Bacterial translocation produced by altered gut integrity has been linked with failure
of immune recovery after initiation of ART.49 Therefore,
as it has been concluded for other conditions, it is important to consider strategies to improve GI integrity and
reduce bacterial translocation by improving the composition of the microbiota through the optimization of probiotic
supplementation.50–52
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878 HIV+ adults in Botswana.

201 children 4–24 months in
South Africa.

674 HIV+ antiretroviral-naïve
Tanzanian women.

594 Tanzanian HIV+ women.

1,129 HIV-infected pregnant
women in Tanzania.

Baum et al (2013)79

Mda et al (2013)99

Arsenault et al (2010)84

Villamor et al (2010)85

Kawai et al (2010)57

915 HIV+ pregnant Tanzanian
women.

420 HIV+ pregnant women
enrolled at 12–27-week
gestation in Tanzania.

Sudfeld et al (2014)82

Kupka et al (2009)58

Population

Authors (year)

Se supplementation increased the relative risk of HIV1 RNA .50 copies/mL detection in breast milk (36%
vs 27.5%) among primiparous but not multiparous
women who were not receiving ART.

200 μg elemental Se (selenomethionine)
All women received multivitamin supplement: 20 mg thiamin, 20 mg riboflavin,
100 mg niacin, 25 mg vit B6, 50 μg vit B12, 0.8 mg folic acid, 500 mg vit C, 30 mg
vit E and standard doses of antenatal folic acid and 120 mg ferrous iron.
Multivitamin supplement: 20 mg thiamin, 20 mg riboflavin, 100 mg niacin, 25 mg
vit B6, 50 μg vit B12, 0.8 mg folic acid, 500 mg vit C, and 30 mg vit E, in one arm,
or multivitamins combined with 200 μg of elemental Se (selenomethionine) in
the second arm, or 200 μg of Se alone in the third arm, or placebo in the fourth
arm.

Vitamin A with b-carotene supplementation in
lactating women increases the HIV load in breast milk.

1) vitamin A with β-carotene (VA/BC): 5,000 IU preformed vitamin A plus 30 mg
β-carotene); 2) multivitamins (20 mg thiamine, 20 mg riboflavin, 25 mg vit B6,
100 mg niacin, 50 μg vit B12, 0.8 mg folic acid, 500 mg vit C, and 30 mg vit E;
3) multivitamins plus VA/BC; or 4) placebo.
Multivitamin supplements: (B complex: thiamin, riboflavin, niacin, B6, B12, and
vitamins C and E) at a single dose of the RI compared to 20 mg thiamin, 20 mg
riboflavin, 100 mg niacin, 25 mg vit B6, 50 μg vit B12, 0.8 mg folic acid, 500 mg vit
C, and 30 mg vit E.
All women received standard doses of antenatal folic acid and 120 mg ferrous
iron.
All newborns received: vit A at 100,000 IU at 6 months and 200,000 IU at the
age of 1 year and every 6 months thereafter.
Supplement: selenomethionine, 200 μg daily, compared to placebo.
All women received: antenatal ferrous iron (60 mg/d), and 20 mg riboflavin,
110 mg niacin, 25 mg vit B6, 50 μg vit B12, 0.8 mg folic acid, 500 mg vit C, and
30 mg vit E.

Supplementation of HIV-infected women with vitamins
increased the risk of subclinical mastitis.

1) vitamin A (1,500 μg RE of retinol) plus 30 mg β-carotene; 2) multivitamins
(20 mg thiamin, 20 mg riboflavin, 25 mg vitamin B6, 100 mg niacin, 50 μg vitamin
B12, 500 mg vitamin C [purified l-ascorbic acid], 30 mg vitamin E [RRR-αtocopherol acetate], and 0.8 mg folic acid); 3) multivitamins with vitamin A plus
β-carotene; or 4) placebo.
All newborns received: vit A at 100,000 IU at 6 months and 200,000 IU at the
age of 1 year and every 6 months thereafter.

(Contined)

Supplementation with Se during pregnancy and
postpartum reduced diarrheal morbidity risk by
40% with no significant risk for anemia. No effect on
morbidity end points.

Supplementation of multivitamins at the
recommended intake (RI) levels is as effective as
multiple doses of the RI in decreasing risk of adverse
pregnancy outcomes among HIV+ women.

Micronutrient supplementation significantly reduced
episodes of diarrhea and respiratory symptoms, and
improved malnutrition.

300 μg retinol, 0.6 mg thiamin, 0.6 mg riboflavin, 8 mg niacin, 0.6 mg
pyridoxine, 1 μg cobalamin, 70 μg folic acid, 25 mg ascorbic acid, 5 μg
1,25-dihydrocholecalciferol, 7 mg d,l-tocopherol, 700 μg copper, 8 mg iron,
30 μg selenium, and 8 mg zinc.

24-Month supplementation with a single supplement
containing multivitamins and selenium was safe and
reduced the risk of immune decline and morbidity
when started in the early stages of HIV disease.

Outcomes

Formula

Table 1 Randomized clinical trials of nutritional supplementation before initiation of ART
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829 HIV+ pregnant and
lactating women in Tanzania,
and their infants up to
24 months of age.

Villamor et al (2007)61

1,078 HIV+ pregnant women in
Tanzania.

471 HIV-positive and 416 HIVnegative adults with pulmonary
TB in Tanzania.

Villamor et al (2008)60

Fawzi et al (2007)62

913 HIV-infected pregnant
women in Tanzania and their
children.

626 HIV+ pregnant women in
Tanzania.

Population

Kupka et al (2008)59

Webb et al (2009)

Authors (year)

Table 1 (Contined)

Multivitamin supplement: 20 mg thiamin, 20 mg riboflavin, 100 mg niacin, 25 mg
vit B6, 50 μg vit B12, 0.8 mg folic acid, 500 mg vit C, and 30 mg vit E, compared to
placebo.
Vitamin A: 30 mg β-carotene + 5,000 IU preformed vitamin A, compared to
placebo.
Combined multivitamins with vit A compared to placebo.
The two groups of women receiving vit A also received a single dose of 200,000
IU of vit A at delivery.
All women received standard doses of antenatal folic acid and 120 mg ferrous
iron.
All newborns received: vit A at 100,000 IU at 6 months and 200,000 IU at the
age of 1 year and every 6 months thereafter.
Multivitamin supplement: 20 mg thiamin, 20 mg riboflavin, 100 mg niacin, 25 mg
vit B6, 50 μg vit B12, 0.8 mg folic acid, 500 mg vit C, 30 mg vit E, compared to
placebo.
Vitamin A: 30 mg β-carotene + 5,000 IU preformed vitamin A, compared to
placebo.

Sustained supplementation of HIV-infected
breastfeeding mothers with this multivitamin
formula is an effective intervention to improve
vitamin E concentrations in breast milk. Although
supplementation with vitamin A and b-carotene
increased concentrations of breast milk retinol, it
was not recommended in HIV+ mothers due to the
elevated risk of vertical transmission.

Women were randomized into one of four formulas:
1. Vit A and β-carotene (VA + BC): 5,000 IU (1,500 μg retinol equivalents) of
preformed vit A plus 30 mg of β-carotene).
2. Multivitamins: 20 mg of thiamine, 20 mg of riboflavin, 25 mg of vit B6, 100 mg
of niacin, 50 μg of vitamin B12, 0.8 mg of folic acid, 500 mg of vit C, and 30 mg of
vit E.
3. Multivitamins plus vit A.
4. Placebo.
The two groups of women who receiving vit A also received a single dose of
200,000 IU of vit A at delivery.
All women received standard doses of antenatal folic acid and 120 mg
ferrous iron.
All newborns received: vit A at 100,000 IU at 6 months and 200,000 IU at the
age of 1 year and every 6 months thereafter.
Supplement: selenomethionine, 200 μg daily, compared to placebo.
All women received: antenatal ferrous iron (60 mg/d), and 20 mg riboflavin,
110 mg niacin, 25 mg vit B6, 50 μg vit B12, 0.8 mg folic acid, 500 mg vit C, and
30 mg vit E.
All newborns received: vit A at 100,000 IU at 6 months and 200,000 IU at the
age of 1 year and every 6 months thereafter.
Multivitamin supplement: 20 mg thiamin, 20 mg riboflavin, 100 mg niacin, 25 mg
vit B6, 50 μg vit B12, 0.8 mg folic acid, 500 mg vit C, 30 mg vit E, and 200 μg of Se,
compared to placebo.

Multivitamin supplementation provided during
pregnancy and in the postpartum period resulted in
significant improvements in hematologic status among
HIV-infected women and their children.

Multivitamin supplementation with selenium increased
CD3+ and CD4+ cell counts and decreased the incidence
of extrapulmonary TB and genital ulcers in HIV-negative
patients. Reduced the incidence of peripheral neuropathy
by 57%, irrespective of HIV status.
Children born to the supplemented women in
the three arms (including vitamin A) significantly
decreased the burden of malaria. Also children
supplemented with vitamin A after 6 months of
delivery and up to 24 months of age had reduced risk
of malaria.

Maternal supplementation with selenium during
pregnancy and postpartum reduced risk of child
mortality after 6 weeks of delivery.

Outcomes

Formula

Sneij et al
Dovepress
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159 HIV-infected adults with
.7 days of diarrhea recruited
at hospitals in Peru.
1,078 HIV+ pregnant women
in Tanzania, and subset of 327
children born to these mothers.

Cárcamo et al (2006)76

Range et al (2006)66

213 patients with TB + HIV,
286 patients with TB and HIVnegative.

400 HIV-infected pregnant
women in Tanzania.

Villamor et al (2006)75

McGrath et al (2006)64

1,078 HIV+ pregnant women.

Smith Fawzi et al
(2007)63

Multivitamin supplement: 20 mg thiamin, 20 mg riboflavin, 100 mg niacin, 25 mg
vit B6, 50 μg vit B12, 0.8 mg folic acid, 500 mg vit C, and 30 mg vit E compared to
placebo.
Vitamin A: 30 mg β-carotene + 5,000 IU preformed vitamin A (alone or with
multivitamins compared to placebo).
Combined multivitamins with vit A compared to placebo.
The two groups of women who received vit A also received a single dose of
200,000 IU of vit A at delivery.
All women received standard doses of antenatal folic acid and 120 mg ferrous
iron.
All newborns received: vit A at 100,000 IU at 6 months and 200,000 IU at the
age of 1 year and every 6 months thereafter.
Multivitamin and mineral supplement: 5,000 IU vitamin A, 20 mg thiamin, 20 mg
riboflavin, 25 mg vit B6, 40 mg niacin, 50 μg vit B12, 0.8 mg folic acid, 200 mg
vitamin C, 60 mg vitamin E, 200 IU vitamin D3, 200 μg Se, 5 mg copper, and
45 mg Zn, compared to placebo.

Supplement: 100 mg of elemental Zn compared to placebo.

Combined multivitamins with vit A compared to placebo.
The two groups of women receiving vit A also received a single dose of
200,000 IU of vit A at delivery.
All women received standard doses of antenatal folic acid and 120 mg ferrous
iron.
All newborns received: vit A at 100,000 IU at 6 months and 200,000 IU at the
age of 1 year and every 6 months thereafter.
Multivitamin supplement: 20 mg thiamin, 20 mg riboflavin, 100 mg niacin, 25 mg
vit B6, 50 μg vit B12, 0.8 mg folic acid, 500 mg vit C, 30 mg vit E, compared to
placebo.
Vitamin A: 30 mg β-carotene + 5,000 IU preformed vitamin A, compared to
placebo.
Combined multivitamins with vit A compared to placebo.
The two groups of women receiving vit A also received a single dose of
200,000 IU of vit A at delivery.
All women received standard doses of antenatal folic acid and 120 mg ferrous
iron.
Supplement: 25 mg of zinc or placebo.
All women received daily: 20 mg thiamin, 20 mg riboflavin, 25 mg vit B6, 100 mg
niacin, 50 μg vit B12, 500 mg vit C, 30 mg vit E, ferrous sulfate 60 mg, and 800 μg
folate.
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Supplementation with multivitamins and minerals,
including Zn, Cu, and Se during treatment of
pulmonary TB reduced mortality in those coinfected
with HIV and TB.

No effect on pregnancy outcomes, or maternal
disease progression. Reduction in maternal midarm
circumference. Potential for promoting anemia.
Recommended not supplementing in HIV+ pregnant
women.
Zn supplementation at this level had no significant
effect on the duration or remission of diarrhea in
HIV+ adults.
Maternal supplementation with multivitamins was
protective against the risk for developmental delay on
the motor scale in children from HIV+ mothers.

Multivitamin supplementation reduced the risk of
elevated depressive symptoms comparable to major
depressive disorder and improvement in quality of life.
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1,078 HIV+ pregnant women in
Tanzania.

1,078 HIV+ pregnant women in
Tanzania.

716 HIV+ mother–infant pairs
in Tanzania.

886 HIV+ mother and their
infants in Tanzania.

Merchant et al (2005)69

Baylin et al (2005)70

Villamor et al (2005)71

96 HIV+ children were
randomized by age-group to
receive Zn sulfate or placebo.

Population

Villamor et al (2005)65

Bobat et al (2005)

Authors (year)

Table 1 (Contined)

submit your manuscript | www.dovepress.com

Supplementation of HIV-infected women with
multivitamins during pregnancy and lactation is an
effective intervention for improving ponderal growth
in their children.

Infants from supplemented mothers, including the
vitamin A arms, compared to placebo, effectively
improved the vitamin status of their children during
the first 6 months of age, including retinol status.

Women in the multivitamin supplementation groups
reduced the risk for developing hypertension by 38%
during pregnancy compared to those who were not
on the multivitamins group.

Children randomly assigned to Zn supplementation
were less likely to get diarrhea than those on placebo
(P=0.001). Supplementation did not have an adverse
effect on viral load.
Supplementation with multivitamins protected against
wasting in HIV+ pregnant women.

Supplement: 10 mg of elemental Zn as sulfate or placebo.

Multivitamin supplement: 20 mg thiamin, 20 mg riboflavin, 100 mg niacin, 25 mg
vit B6, 50 μg vit B12, 0.8 mg folic acid, 500 mg vit C, 30 mg vit E compared to
placebo.
Vitamin A: 30 mg β-carotene + 5,000 IU preformed vitamin A (alone or with
multivitamins compared to placebo).
Combined multivitamins plus vit A compared to placebo.
All women received standard doses of antenatal folic acid and 120 mg ferrous iron.
Multivitamin supplement: 20 mg thiamin, 20 mg riboflavin, 100 mg niacin, 25 mg
vit B6, 50 μg vit B12, 500 mg vit C, 30 mg vit E, and 0.8 mg folic acid (compared
to placebo).
Vitamin A: 30 mg β-carotene + 5,000 IU preformed vitamin A (alone or with
multivitamins compared to placebo).
All women received standard doses of antenatal folic acid and 120 mg ferrous iron.
Multivitamin supplement: 20 mg thiamin, 20 mg riboflavin, 100 mg niacin, 25 mg
vit B6, 50 μg vit B12, 500 mg vit C, 30 mg vit E, and 0.8 mg folic acid (compared
to placebo).
Vitamin A: 30 mg β-carotene + 5,000 IU preformed vitamin A (alone or with
multivitamins compared to placebo).
The two groups of women receiving vitamin A also received a single dose of
200,000 IU of vitamin A at delivery.
All newborns received standard 200,000 IU or 100,000 IU if ,1 year of age of
vitamin A. All women received standard doses of antenatal folic acid and 120 mg
ferrous iron.
All newborns received: vit A at 100,000 IU at 6 months and 200,000 IU at the
age of 1 year and every 6 months thereafter.
Multivitamin supplement: 20 mg thiamin, 20 mg riboflavin, 100 mg niacin, 25 mg
vit B6, 50 μg vit B12, 500 mg vit C, 30 mg vit E, and 0.8 mg folic acid (compared
to placebo).
Vitamin A: 30 mg β-carotene + 5,000 IU preformed vitamin A (alone or with
multivitamins compared to placebo).
The two groups of women receiving vitamin A also received a single dose of
200,000 IU of vitamin A at delivery.
All newborns received standard 200,000 IU or 100,000 IU if ,1 year of age of
vitamin A. All women received standard doses of antenatal folic acid and 120 mg
ferrous iron.
All newborns received: vit A at 100,000 IU at 6 months and 200,000 IU at the
age of 1 year and every 6 months thereafter.

Outcomes

Formula

Sneij et al
Dovepress
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1,078 pregnant HIV+ women.

400 HIV+ women in Kenya.

1,078 pregnant HIV+ women.

481 HIV-infected men and
women in Thailand with CD4
cell counts in the range of
50–550 cells/mm3.

1,078 pregnant HIV+ women.

Fawzi et al (2004)25

McClelland et al
(2004)68

Fawzi et al (2003)72

Jiamton et al (2003)24

Fawzi et al (2002)81

Multivitamin supplement: 20 mg thiamin, 20 mg riboflavin, 100 mg niacin, 25 mg
vit B6, 50 μg vit B12, 500 mg vit C, 30 mg vit E, and 0.8 mg folic acid (compared
to placebo).
Vitamin A: 30 mg β-carotene + 5,000 IU preformed vitamin A (alone or
with multivitamins compared to placebo). The two groups of women
receiving vitamin A also received a single dose of 200,000 IU of vitamin
A at delivery.
All women received standard doses of antenatal folic acid and iron.
Multivitamin and selenium supplement: 20 mg thiamin, 20 mg riboflavin, 25 mg vit
B6, 100 mg niacin, 50 μg vit B12, 500 mg vitamin C, 30 mg vitamin E, 0.8 mg folic
acid, and 200 μg of Se, compared to placebo.
Multivitamin supplement: 20 mg thiamin, 20 mg riboflavin, 100 mg niacin, 25 mg
vit B6, 50 μg vit B12, 500 mg vit C, 30 mg vit E, and 0.8 mg folic acid (compared
to placebo).
Vitamin A: 30 mg β-carotene + 5,000 IU preformed vitamin A (alone or
with multivitamins compared to placebo). The two groups of women
receiving vitamin A also received a single dose of 200,000 IU of vitamin A at
delivery.
All women received standard antenatal folic acid and iron.
All newborns received: vit A at 100,000 IU at 6 months and 200,000 IU at the
age of 1 year and every 6 months thereafter.
Multivitamin and Mineral supplement:
Vitamins: 3,000 μg vitamin A, 6 mg β-carotene, 20 μg or 800 IU vitamin D3,
80 mg vitamin E, 180 μg vitamin K, 400 mg vitamin C, 24 mg thiamin, 15 mg
riboflavin, 40 mg vitamin B6, 30 μg vitamin B12, 100 μg folacin, and 40 mg
panthothenic acid. Minerals: 10 mg Fe, 200 mg mg, 8 mg Mn, 30 mg Zn, 300 μg
iodine, 3 mg Cu, 400 μg Se, 150 μg Cr, and 66 mg cysteine compared to
placebo.
Multivitamin supplement: 20 mg thiamin, 20 mg riboflavin, 100 mg niacin, 25 mg
vit B6, 50 μg vit B12, 500 mg vit C, 30 mg vit E, and 0.8 mg folic acid (compared
to placebo).
Vitamin A: 30 mg β-carotene + 5,000 IU preformed vitamin A (alone or with
multivitamins compared to placebo).
The two groups of women receiving vitamin A also received a single dose of
200,000 IU of vitamin A at delivery.
All newborns received standard 200,000 IU or 100,000 IU if ,1 year of age of
vitamin A. All women received standard doses of antenatal folic acid and 120 mg
ferrous iron.
All newborns received vitamin A at 100,000 IU at 6 months and 200,000 IU at
the age of 1 year and every 6 months thereafter.

Nutrition and Dietary Supplements 2016:8

(Contined)

Vitamin A supplementation increased mother-to-child
transmission (RR =1.38, P=0.009) and had no effect
on mortality after 24 months of supplementation.
Multivitamin supplementation, however, reduced
transmission risk in mothers with low CD4 cell count,
low hemoglobin, and low-birth-weight newborns.
Multivitamins also reduced mortality and increased
survival in HIV-negative children born to malnourished
HIV+ mothers with advanced disease.

Multiple micronutrient supplementation improved
the survival of HIV-infected individuals with CD4 cell
counts ,200 cells/mm3.

Supplementation resulted in higher CD4 and CD8
cell counts in the supplemented group, but increased
participants’ genital shedding.
Supplementation with multivitamins prenatally and
during breastfeeding seems to be protective of
adverse pregnancy and child outcomes.

Supplementation with multivitamins delayed
progression to WHO stage 4 (P=0.02), progression
to stage 3 or higher (P=0.003). Multivitamins also
resulted in significantly higher CD4+ and CD8+ cell
counts and significantly lower viral loads.
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697 HIV+ pregnant women in
Malawi.
Kumwenda et al
(2002)98
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Abbreviations: ART, antiretroviral treatment; HIV+, HIV positive; HAAT, highly active antiretroviral therapy; vit, vitamin; TB, tuberculosis; IU, international units; WHO, World Health Organization.

Vitamin A-supplemented pregnant women delivered
higher birth-weight infants, and had fewer anemic
infants at 6 weeks postpartum compared to placebo.
Vitamin A supplementation did not affect mother-tochild perinatal HIV transmission.

In pregnancy, supplementation with multivitamins,
including multivitamins plus vitamin A, compared to
placebo, and improved the rate of weight gain by 27%
during the third trimester of pregnancy.
1,075 pregnant women.
Villamor et al (2002)80

Multivitamin supplement: 20 mg thiamin, 20 mg riboflavin, 100 mg niacin, 25 mg
vit B6, 50 μg vit B12, 500 mg vit C, 30 mg vit E, and 0.8 mg folic acid (compared
to placebo).
Vitamin A: 30 mg β-carotene + 5,000 IU preformed vitamin A (alone or with
multivitamins compared to placebo).
The two groups of women receiving vitamin A also received a single dose of
200,000 IU of vitamin A at delivery.
All newborns received standard 200,000 IU or 100,000 IU if ,1 year of age of
vitamin A. All women received standard doses of antenatal folic acid and 120 mg
ferrous iron.
All newborns received: vit A at 100,000 IU at 6 months and 200,000 IU at the
age of 1 year and every 6 months thereafter.
The experimental group received 3 mg of retinol equivalent daily from the time
of enrolment into the study to delivery. All women received standard 30 mg of
elemental iron and 400 μg folate orally.

Population
Authors (year)

Table 1 (Contined)

Formula

Outcomes

Sneij et al

Nutritional interventions need to be individualized to
the signs and conditions manifested by the patient, before
or coadministered with ART, to preserve the innate immune
response, support the recuperation of the immune system,
and prevent comorbidities.25
Micronutrient deficiencies associated with untreated
HIV infection are vitamins A, C, E and D, B vitamins, and
antioxidant minerals: selenium and zinc.29,33,34,53–55 Although
a Cochrane review56 found no definite evidence of the role
of nutritional supplementation on morbidity, mortality,
and HIV disease progression among PLWH, and vitamin
A supplementation seems to be beneficial only in children, subsequent reports from RCTs of supplementation
have found benefits for both adults and children.23–25,39,57–72
ART and nutritional supplementation are not in contradiction, as concluded by another review,73 as each of them
support the recovery of the immune system by different
mechanisms.
This review focuses on evaluating RCTs of supplementation and their outcomes. Most of the RCTs reviewed had
limitations, due to differences in length of supplementation,
lack of measures of plasma levels of the supplemented micronutrients at baseline, diversity of the nutrients included in the
formulas, and the variety in doses.
A number of RCTs reviewed also reported adverse
unintentional outcomes of supplementation, such as the
association of vitamin A supplementation with increased
mother-to-child transmission,25 iron with increased mortality,74 selenium with vaginal HIV-shedding,68 zinc with
wasting in pregnant women receiving 25 mg of zinc,75
and zinc in a dose of 100 mg elemental zinc/d with
more frequency of diarrhea in patients with diarrheal
condition.76
Reports from RCTs that supplemented multivitamins
with minerals demonstrated better outcomes than supplementation with a single nutrient.77 Supplementation with
multiple nutrients compared to a single nutrient on HIV
disease outcomes suggests a synergistic interaction among
nutrients (Tables 1 and 2), especially with nutritional
antioxidants with a high level of metabolic interactions.73
Because the efficacy of nutritional supplementation on
HIV-disease parameters changes with the use of ART, the
trials of supplementation were divided into two categories:
trials in ART-naïve populations (Tables 1 and 3) and trials
in which supplementation was coadministered with ART
(Tables 2 and 3).
Some of the RCT formulas from the reviewed articles
contained nonnutritional substances that were not directly
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31 HIV+ patients with
immunological discordance
(controlled viral load, CD4 cell
count ,200 cells/μL).
45 HIV+ adults in Cleveland
(OH, USA) on ART and vit D
deficiency.
3,418 HIV+ initiating ART.

Asdamongkol
et al (2013)102

Nutrition and Dietary Supplements 2016:8

231 HIV+ adults in Miami, FL,
USA. 62.3% were on ART.

56 HIV+ children and
adolescents aged 6–16
years with serum 25-OHD
$12 ng/mL, on ART.
262 HIV+ adults in Miami.
Mixed ART, 26.5% with no ART
at baseline.
331 HIV+ patients in advanced
disease (CD4 cell count ranged
from 28 cells/mm3 to 114 cells/
mm3) in Canada, and who
were on combination protease
inhibitor-based ART for at
least 3 months.

Baum et al
(2010)39

Arpadi et al
(2009)88

Austin et al
(2006)86

Hurwitz et al
(2007)67

54 HIV+ children, 3–18 years
old.

Kakalia et al
(2011)90

Isanaka et al
(2012)87

Longenecker et al
(2012)89

Population

Author (year)

Double-blinded RCT,
multicenter (22 clinics).
Supplementation for
13 months.

RCT of supplementation for
9 months.

Nonblinded RCT of
supplementation for
6 months.
Double-blinded RCT
of supplementation for
18 months.
RCT of supplementation for
12 months.

Double-blinded RCT
of supplementation for
12 weeks.
Double-blinded RCT
of supplementation for
24 months.

RCT of supplementation for
6 months. Zn plasma levels
were obtained at baseline.

Design

All participants received: β-carotene 30,000 IU
(18 mg), 1,500 IU vit A, 56 IU vit D, 63 mg vit C, 56
IU vit E, 9.38 mg thiamin, 4.68 mg riboflavin, 2.25 mg
riboflavin–50-phosphate sodium, 3.75 mg niacin,
9.38 mg niacinamide, 18.75 mg d-calcium pantothenate,
9.38 mg vit B6, 3 mg vit B6 (pyridoxine-50-phosphate),
0.08 mg folacin, 0.06 mg biotin, 9.38 mg choline
bitartrate, 37.5 mg mg, 7.5 mg Zn, 1.5 mg Fe, 0.38 mg
Cu, 1.5 mg mg, 9.38 mg K, 0.018 mg Cr, 0.018 mg Se,
0.00938 mg Mb, 0.00938 mg V, and 0.00938 mg I.
Nonnutritional antioxidants: 150 mg N-acetyl-l-cysteine
and 37.5 mg reduced glutathione.
The treatment group also received: the formula above
plus 72 mg of β-carotene/d.

Supplement: selenium yeast providing 200 μg
elemental selenium daily, compared to placebo.

Supplement: vitamin D (100,000 IU/every 2 months)
and calcium 1 g/d (N=29) or placebo daily (N=27).

Multivitamin supplements: low dose: 1.2 mg of
thiamin, 1.2 mg of riboflavin, 15 mg of niacin, 1.3 mg
of vit B6, 2.4 μg of vit B12, 500 mg vit C, and 15 mg
of vit E at a single dose of the RI compared to high
dose: 20 mg of thiamin, 20 mg of riboflavin, 100 mg
of niacin, 25 mg of B6, 50 μg of B12, 0.8 mg folic acid,
500 mg vit C, and 30 mg vit E.
One group received no supplementation, the
second group received 5,600 IU/wk of vitamin D
the third group received 11,200 IU/wk of vitamin D.
Supplement: Zn gluconate (12 mg for females and
15 mg for males) compared to placebo.

Vitamin D3 4,000 IU daily or placebo.

Daily supplementation – 15 mg of chelated Zn
compared to placebo.

Formula

Table 2 Randomized clinical trials of supplementation among people living with HIV, who were receiving ART

(Contined)

β-Carotene supplementation, in addition
to the multivitamin/mineral/nonnutrient
antioxidant formula, reduced mortality
by more than three times (3.15 [1.10,
8.98], P=0.03) in those with advanced HIV
disease after adjusting for baseline CD4
cell count and serum carotene.

Vitamin D supplementation in doses of
11,200 IU/wk or higher does not impact
CD4 count.
Prevented immune failure (CD4 cell count
,200 cells/mm3) and decreased diarrhea
over time.
Supplementation was safe, did not affect
viral control or disease progression, and
resulted in significant increases in serum
vitamin D concentrations.
Daily Se supplementation suppressed the
increase of viral burden and provided
indirect improvement in CD4 cell count.

The CD4+ cell count significantly
increased (P=0.042) after zinc
supplementation in patients with low
plasma zinc levels at baseline (N=12).
Improved vitamin D status and cholesterol
but worsened insulin resistance without
change in endothelial function.
Receiving high-dose supplementation,
compared to low dose, increased the
relative risk of higher ALT levels by 44%,
with no differential effect on disease
progression. The study was stopped early.

Outcomes

Dovepress
Clinical trials of nutritional supplementation in HIV Infection

submit your manuscript | www.dovepress.com

Dovepress

29

Dovepress

30

Powered by TCPDF (www.tcpdf.org)

submit your manuscript | www.dovepress.com

Dovepress

Abbreviations: ART, antiretroviral treatment; HIV+, HIV positive; RCT, randomized clinical trial; vit, vitamin; 25-OHD, 25-hydroxyvitamin D; RI, Recommended Intake; wk, week; Se, selenium supplementation; IU, international units;
ALT, alanine aminotransferase.

Nutritional supplementation in HIV+
patients on stable ART significantly
increased CD4 cell counts after 12 weeks
and experienced some reduction of
neuropathy.
Nonnutritional antioxidants: 1,200 mg N-acetyl
cysteine, 100 mg acetyl-l-carnitine, and 400 mg
α-lipoic acid.
Vitamins: vit A 8,000 IU, β-carotene 20,000 IU, vit
C 1,800 mg, 60 mg thiamin, 60 mg riboflavin, 60 mg
pantothenic acid, 60 mg niacinamide, 60 mg inositol,
50 μg biotin, 260 mg vit B6, 2.5 μg vit B12, 400 IU
vit D, 800 IU vit E, 300 mg bioflavonoids, 800 μg
folate, and 60 mg choline.
Minerals: 800 mg Ca, 18 mg Fe, 30 mg Zn,
400 mg mg, 200 μg Se, 150 μg I, 100 μg Cr, 10 mg
Mn, 2.0 mg Cu, 300 μg Mb, 2.0 mg vit B, 99 mg K,
and 150 mg betaine HCL.
40 HIV+ patients.

Outcomes
Formula

Double-blinded RCT,
comparing a formula to
placebo. Supplementation
for 12 weeks.
Kaiser et al
(2006)23

Design
Population
Author (year)

Table 2 (Continued)

Sneij et al

addressed in this review and which are listed as nonnutrients
in Tables 1 and 2. The observational research on these
nonnutrient substances is scarce, and their evaluation is
beyond the focus of this review.

Methods
This review followed the five steps of the Academy of
Dietetics and Nutrition for conducting evidence-based
review.78 A systematic search of literature was conducted
using PubMed and the resources of the Florida International
University Library, including the Expanded Academic
ASAP, Academic OneFile, Student Resources in Context,
and Academic Search Complete to identify high-quality
primary reports from RCTs of micronutrient and probiotic
supplementation (Figure 1). The RCT design is considered
to provide the strongest evidence.78 The inclusion criteria
for articles reviewed here were primary reports of RCTs
in HIV-seropositive patients, $30 participants, published
in the last 15 years, in English, and with and without coadministration of ART. Articles that did not meet the inclusion
criteria were excluded after examination. The keywords
used were HIV, nutrition, supplementation, RCT, micronutrients, vitamin, mineral, probiotic, and microbiota in different combinations to foster a wide number of results. The
final selection included 42 reports of RCTs of nutritional
supplementation in PLWH. These were divided into two
categories: those conducted prior to the initiation of ART
(n=31) and those in which nutritional supplementation was
coadministered with ART (n=11).
The research questions that guided the review were
• Is nutritional supplementation beneficial in PLWH before
and after the initiation of ART?
• How the objectives of the intervention differ before and
after receiving ART?

Results
The majority of the formulas described in the reviewed
reports (Tables 1–3) included several levels of B
vitamins (thiamin, riboflavin, niacin, B 6 , B 12 , and
folate)23,25,57–66,68–72,79–87 as these are important in the energy
cycle of the mitochondria and for prevention of mitochondrial oxidative stress. Other antioxidant nutrients
such as vitamins A, C, and E, selenium, and zinc were
also included because the immune response to a chronic
infection and some ART combinations may aggravate
mitochondrial and systematic oxidative stress.15–19 Calcium
and vitamin D were included in the formulas provided to
cohorts that were coadministered ART23,88–90 because some
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Table 3 Randomized clinical trials of probiotic supplementation
Authors (year)

Population

In PLWH (pre-ART)
Hummelen et al
112 ART-naïve HIV
(2011)103
patients in Tanzania

Hummelen et al
(2010)104

65 HIV+ women with
aberrant microbiota in
Tanzania (Nugent score
4–10)

In HIV population (post-ART)
Van Niekerk et al
74 HIV-exposed and 110
(2014)105
nonexposed premature
(,34-week gestation)
infants with a birth
weight of $500 g and
#1,250 g in Cape Town,
South Africa

Villar-García et al
(2015)106

44 PLWH with
controlled viral load
,20 copies/mL

Design

Formula

Outcomes

Randomized, doubleblind, controlled trial of
micronutrient and yogurt
for 4 weeks

Micronutrient fortified yogurt with/
without additional probiotic. Amount pert
125 g of yogurt: Lactobacillus rhamnosus
GR-1 at 109 CFU/mL; vit A at 1,500 IU; vit E
at 5.7 IU; niacinamide at 3.8 mg; thiamin at
0.3 mg; vit B12 at 0.6 μg; vit B6 at 0.3 mg;
vit C at 21 mg; iron at 3.3 mg; selenium at
13.8 μg; zinc at 2.4 mg; DHA (omega-3) at
13 mg, and EPA (omega-3) at 19 mg
L. rhamnosus GR-1 and Lactobacillus reuteri
RC-14 supplementation compared to
placebo

Micronutrient fortified
yogurt was well
tolerated by PLWH but
not associated with a
further increase in CD4
count after 4 weeks of
supplement

Randomized, double-blind,
placebo-controlled trial
supplemented for 28 days

Study group: breast milk plus a daily
probiotic supplement of L. rhamnosus GG
(0.35×109 colony-forming units [CFU]) and
Bifidobacterium infantis (0.35×109 CFU);
control group: breast milk plus a placebo
consisting of medium-chain triacylglycerol
(MCT) oil

Double-blind, randomized,
placebo-controlled trial

Oral supplementation with probiotics
(Saccharomyces boulardii) or placebo for
12 weeks

Probiotics did not affect
growth outcomes or
incidence of feeding
intolerance in HIVexposure infants, but
they had significantly
higher Z-scores for
length and head
circumference than the
unexposed newborns at
the end of the study
S. boulardii treatment
decreased microbial
translocation (LBP)
and inflammation (IL-6)
in HIV-1-infected
patients with long-term
virologic suppression

Randomized, double-blind,
placebo-controlled trial
for 6 months

Supplementation of
probiotic L. rhamnosus
GR-1 and L. reuteri
RC-14 did not enhance
the cure of bacterial
vaginitis but significantly
increased beneficial pH
(OR =3.8, P=0.02)

Abbreviations: PLWH, people living with HIV; ART, antiretroviral treatment; vit, vitamin; HIV+, HIV positive; OR, odds ratio; LBP, lipopolysaccharide-binding protein; IL-6,
interleukin 6; EPA, eicosapentaenoic omega-3 fatty acid; DHA, decosahexaenoic omega-3 fatty acid.

of the treatment combinations, and HIV itself, seem to
expose PLWH to bone mass losses.91–96 These nutrients
were supplemented either at the Recommended Dietary
Allowance (RDA) levels97 or at several times the RDA
values. Summarizing the conclusions is difficult because
of the various supplements provided in each trial and the
lack of dose–response studies, but most outcomes of the
studies that included these micronutrients showed that
they were effective in delaying HIV disease progression and safe in ART-naïve populations (Table 1) and
after ART initiation when given at nutritional doses (one
RDA or under Tolerable Upper Intake Levels) (Table 2).
Table 3 describes the trials that included probiotics in
their formula.

Nutrition and Dietary Supplements 2016:8

RCTs of micronutrients in ART-naïve
PLWH
Of the 29 RCTs reviewed in Table 1, 15 reports are from a
longitudinal RCT of supplementation conducted in Tanzania,
which included 1,078 HIV-infected, ART-naive pregnant
women who were followed for a median of 71 months.
These pregnant women received 30 mg β-carotene + 5,000
IU preformed vitamin A alone, or a multivitamin with
B vitamins and vitamins C and E alone, or a combination of both, or placebo in a 2×2 factorial design. In this
trial, their newborns were followed for 18–24 months and
supplemented with standard 100,000 IU of vitamin A at
6 months and 200,000 IU at 1 year of age and every 6 months
thereafter.25,61–65,69–72,80,81,84,85
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The majority of the 15 articles reported benefits such as a
reduction in the risk of vertical transmission with multivitamin supplementation, but not with vitamin A, in mothers with
a low CD4 cell count, low hemoglobin and low-birth-weight
newborns, and that multivitamin supplementation increased
the survival of HIV-negative newborns of malnourished
mothers with advanced HIV disease.81 Multivitamins alone
or with vitamin A improved maternal weight gain during
the third trimester of pregnancy.80 Multivitamins during
pregnancy and breastfeeding reduced adverse pregnancy and
child outcomes,72 including improving newborns’ ponderal
weight71 and vitamin E status,83 protecting infants against
motor developmental delays,64 reducing maternal wasting,65
hypertension,69 symptoms of depression, improving women’s
quality of life,63 delaying HIV disease progression during
pregnancy,25 and improving hematological outcomes in both
mothers and infants. Supplementation with vitamin A during
pregnancy improved the vitamin A status of infants.70 The
three supplementation arms, including those with vitamin A,
decreased the burden of malaria in this cohort.61 Other reports
from this trial, however, also described adverse effects, such
as increased vertical transmission and increased viral load

Selection of
articles for review
Excluded because
did not meet
inclusion criteria
(n=184)

in breast milk with vitamin A supplementation, without
reduction in mortality,81,83–85 and risk of developing subclinical mastitis with multivitamins.84 In contrast, Kumwenda
et al98 randomized a cohort of 697 pregnant women in Malawi
to receive 3 mg daily of retinol or placebo, in addition to the
standard iron and folate supplementation during pregnancy,
and concluded that supplementation during pregnancy and
postpartum had beneficial effects on newborns’ birth weight
and prevention of anemia, without changing the rate of
mother-to-child transmission.
Baum et al79 supplemented 878 PLWH in Botswana with
a multivitamin formula (a B complex with vitamins C and
E based on that used by Fawzi et al25) in a double-blinded
RCT with a 2×2 factorial design. The participants were randomized to selenium (200 µg of elemental selenium) alone
in the first arm of the study, or to multivitamins alone in the
second arm, or multivitamins and selenium in combination
in the third arm, compared to placebo. The participants
were followed for 24 months, and the end points were CD4
cell count ,250 cells/µL, AIDS-defining conditions, and
combinations of both end points as a parameter of HIV disease progression. The supplementation of multivitamin and

Number of articles found using key words:
HIV, nutrient supplement, and RCT (n=226)
Assessment of eligibility by inclusion criteria:
• RCTs of supplementation
• English language
• Published from 2001 to present
• PLWH with sample size >30
participants
Articles selected for review (n=42)

Allocation
according to ART
Allocated to group of RCTs of
PLWH prior to receiving ART
(n=31)

Allocated to group of RCTs of
PLWH receiving ART
(n=11)

RCTs with
micronutrients
Allocated to group of RCT prior to
receiving ART that supplemented
micronutrients (n=29)

Allocated to group of RCT
receiving ART that supplemented
micronutrients (n=9)

RCTs with probiotics
Probiotics without ART (n=2)

Probiotics with ART (n=2)

Figure 1 Consort flow diagram.
Abbreviations: RCT, randomized clinical trial; PLWH, people living with HIV; ART, antiretroviral treatment.
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selenium was safe and reduced the risk of immune decline
and morbidity (Table 1). These findings were consistent with
those of Jiamton et al24 who reported that supplementation
with a complex formula with micronutrients and cysteine
improved the survival of persons with advanced HIV disease
(,200 cells/µL).
Sudfeld et al,82 using the multivitamin formula previously
described by Fawzi et al25 and Baum et al79 (B complex with
vitamins C and E), compared the multivitamin arm with an
experimental arm with multivitamins plus 200 µg of selenium, in a cohort of 420 pregnant women enrolled at 12–27week gestation and followed until 6 months postpartum.
The authors found that in primiparous women, but not in
multiparous, the addition of selenium increased the relative
risk of HIV-RNA shedding in breast milk.
In a cohort of 915 HIV-positive pregnant women, who
were supplemented with multivitamins and selenium in a
design similar to that of Sudfeld et al,82 Kupka et al58 found
that those who were supplemented with selenium had 40%
fewer episodes of diarrhea without increased risk of anemia.
In another report from this trial,59 the investigators reported a
reduced risk of mortality at 6 weeks after birth in children born
to women supplemented with selenium and multivitamins.
McClelland et al68 also supplemented a similar formula to
HIV-positive women in Kenya, and they found improvement
in immune measures in those receiving the multivitamin with
selenium formula (CD4 cell count + 23 cells/µL, P=0.03; and
CD8 cell counts + 74 cells/µL, P=0.005) compared to placebo;
however, they also reported an increase in HIV genital shedding among women receiving the formula.
The same formula of multivitamins with B vitamins
and vitamin C and E25,79 was also combined with 25 mg of
zinc, which is only slightly higher than the RDA recommendation (8 mg of zinc for women and 11 mg for men)
and compared to placebo.75 The experimental formula did
not affect pregnancy outcomes or HIV disease progression. Villamor et al75 also reported reduction in maternal
midarm circumference, which suggested losses in fat or
muscle mass in pregnant women receiving zinc with the
multivitamin formula. Mda et al99 randomized 201 children
aged 4–24 months into a micronutrient formula appropriate
for age or placebo for 6 months, and reported that those
randomized into the micronutrient formula significantly
reduced episodes of diarrhea, respiratory symptoms, and
improved nutritional status.
Bobat et al100 randomized 96 children with HIV disease to
receive 10 mg of elemental zinc or placebo. The children who
received the zinc dose were less likely to get diarrhea and did
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not experience an increase in their viral load. In comparison,
Cárcamo et al76 supplemented 159 adults with HIV with a
high dose of zinc (100 mg of elemental zinc) during episodes
of diarrhea and did not find an effect on the duration or
remission of diarrhea. The comparison of these two studies
suggest that zinc supplementation, at lower doses and as
prevention, is more effective than during episodes of diarrhea
at a very high dose.
In an attempt to clarify the differential effects between
high and nutritional doses of multivitamin supplementation,
Kawai et al57 compared a multivitamin formula that offered B
vitamins and vitamins C and E at the Recommended Intake
levels with the B vitamins and vitamins C and E used in
higher doses in the aforementioned trials. No differences in
adverse pregnancy outcomes were found between the two
arms of the study.
In resource-limited countries, tuberculosis (TB) is a significant cause of mortality in PLWH without ART. PLWH
who receive isoniazid medication, either as prevention or
treatment of TB, may need supplementation with vitamin B6.
Receiving lower doses of isoniazid to prevent TB, or in high
doses to treat it, may stir symptoms of neuropathy, because
the medication blocks the absorption and metabolism of
vitamin B6. Supplementation with vitamin B6 was found
effective to prevent the symptoms of neuropathy associated
with treatment.101 Villamor et al60 conducted an RCT of multivitamins with B6 and selenium compared to placebo among
a cohort of 887 participants with pulmonary TB that included
471 HIV/TB-coinfected people. The authors reported a reduction in peripheral neuropathy by 57% in TB patients with and
without HIV, which is consistent with Kaiser et al23 (Table 2),
who supplemented 40 PLWH receiving ART with a complex
formula containing 260 mg of B6 and reported improvement
in neuropathy in patients on a stable ART combination associated with this condition.

RCTs of micronutrients in PLWH
receiving ART
Two-thirds of the studies described in Table 2, after the
initiation of ART, used single nutrients such as zinc, selenium, calcium, and vitamin D, which have been recognized
to be deficient after initiation of ART.39,67,88,90,102 However, the articles led by Isanaka et al,87 Austin et al,86 and
Kaiser et al23 reported the use of multiple combinations of
multivitamins.
Isanaka et al87 compared a low dose to a high dose of
the same formula of multivitamins supplemented to ARTnaive patients in Africa25,79 and concluded that the high dose
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increased liver transaminases without having a significantly
different effect on HIV disease progression. Austin et al86
compared a complex formula with multivitamins, minerals,
and nonnutritional antioxidants with the same complex
formula with an added higher dose of vitamin A and
supplemented for 13 months. This was a multisite RCT in
PLWH in advanced disease stage, receiving an ART combination containing protease inhibitors for at least 3 months.
All participants received multivitamins and nonnutritional
antioxidants as shown in Table 2. The investigators reported
a reduced rate of mortality (odds ratio =3.15, P=0.03) in
the group that received 120,000 IU (72 mg) of β-carotene
compared to those who only received the standard formula,
after controlling for serum carotene and CD4 cell count at
baseline.86
Kaiser et al23 conducted a clinical trial of PLWH on stable
ART using a complex formula with multivitamins, minerals,
and nonnutritional antioxidants compared to placebo for
12 weeks. The investigators found that, compared to placebo,
those who received the formula showed a significant increase
in CD4 cell counts, with some reduction in neuropathy.
Two of the RCTs of supplementation addressed zinc
deficiency in PLWH on ART. In a report from an RCT of
zinc supplementation for 6 months, Asdamongkol et al102
randomized into zinc or placebo supplementation a group
of 31 PLWH with immunological discordance (achieving
controlled viral load without increasing CD4 cell count
.200 cells/µL) and found that CD4 cell counts significantly
increased in patients who started the study with low plasma
levels of zinc. These findings agreed with those of a much
larger study by Baum et al39 of 231 adults living with HIV,
who used illicit drugs, and were zinc deficient at randomization. The participants received either zinc at the level of 12 mg
of elemental zinc for women or 15 mg for men or placebo for
18 months. Zinc supplementation prevented immune failure
and decreased episodes of diarrhea.
As vitamin D deficiency has been identified as one of
the side effects of long-term antiretroviral use, three of the
reports of micronutrient supplementation after ART focused
on vitamin D supplementation alone or with calcium.88–90
Arpadi et al88 randomized 56 children living with HIV and
receiving ART into 100,000 IU of vitamin D every 2 months
and 1 g of calcium daily or placebo during 1 year; the investigators concluded that the intervention did not significantly
affect viral control or HIV disease progression, but serum
vitamin D significantly increased in those supplemented.
Longenecker et al89 investigated the effects of supplementation with vitamin D on the endothelial function in
PLWH. The study was an RCT that included 45 HIV patients
34
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on ART therapy. Participants were randomized into the
intervention group, which received 4,000 IU vitamin D3,
or into the placebo group and followed for 12 weeks. There
was no difference in flow-mediated brachial artery dilation
between the two groups (P=0.748). Serum vitamin D levels
significantly increased in the intervention group (P=0.003)
and total and non-HDL cholesterol were reduced. Interestingly, vitamin D supplementation was also associated with
increased insulin resistance. Further investigation on this
relationship is warranted.
Kakalia et al90 also evaluated the effect of vitamin D
supplementation on CD4 cell count in 54 children living
with HIV, who were randomized into three groups: 800 IU
of vitamin D/d, 1,600 IU of vitamin D/d, or no supplementation. Serum vitamin D levels significantly increased
in the 800 IU/d (P=0.0002) and 1,600 IU/d (P,0.001)
supplementation groups compared with control. Although
vitamin D supplementation increased serum levels, CD4 cell
count did not increase. The investigators also concluded that
for maintaining adequate vitamin D levels in HIV-infected
children, intakes of ∼1,600 IU/d may be required. More
longitudinal research is needed to identify potential risk factors for changes in bone mineral density in PLWH receiving
specific ART combinations and develop effective medical
and nutritional interventions.

RCTs of probiotic supplementation in
PLWH
There have been very few trials of supplementation with probiotics before initiation103,104 or concomitant with ART105,106
in PLWH (Table 3). The majority of these trials were limited
by small sample size, short duration of supplementation and
one was combined with micronutrient supplementation.105
Hummelen et al103,104 in two reports of RCTs conducted in
ART-naive patients in Tanzania supplemented Lactobacillus
rhamnosus GR-1. In the 2011 article, 112 participants
received yogurt in combination with a multivitamin/mineral
formula with omega-3 fatty acids, and the experimental
group also received L. rhamnosus GR-1 at 109 CFU/mL. The
investigators found that the fortified yogurt was well tolerated but did not significantly increase CD4 cell count. The
main weakness of this study was that supplementation only
occurred for 4 weeks, probably a very short time to observe
long-term outcomes. A longer trial of supplementation of
probiotics for 6 months by these investigators in Tanzania106
found that supplementation with L. rhamnosus GR-1 and
L. reuteri RC-14 did not seem to have an effect on bacterial
vaginitis but changed the vaginal pH in a beneficial manner
that may prevent the condition.
Nutrition and Dietary Supplements 2016:8
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Discussion
A Cochrane review that combined the results from the trials
of vitamin A supplementation among pregnant women living
with HIV determined that supplementation with vitamin A did
not reduce or prevent mother-to-child HIV-1 transmission.107
However, other investigators have confirmed benefits in other
pregnancy outcomes such as improved birth weight, and
lower rates of infant morbidity and mortality.72,73 A review by
Mehta and Fawzi,55 which concurred with a 2005 Cochrane
review,57 reported that vitamin A supplementation should be
recommended, because it was beneficial in reducing all-cause
mortality and morbidity in infants and children infected with
HIV. In adults, vitamin A supplementation in excess of the
RDA is not recommended due to its adverse effects on motherto-child transmission, increased HIV breast milk shedding
and lack of effect on HIV disease progression.
The majority of studies in PLWH in Table 1, who were
ART-naive, used formulas of multivitamins in factorial
designs compared to single nutrients or to a combination of
multivitamins plus the specific single nutrients or placebo. In
contrast, most of the studies after the initiation of ART used
single nutrients such as zinc, selenium, calcium and vitamin
D, which have been recognized to be deficient after initiation of ART.39,67,88–90,102,105,106 The report from Isanaka et al87
suggests that supplementation with multivitamin at the RDA
level is still safe in coadministration with ART, but high doses
of vitamins should be avoided.
Another study assessed the effect of vitamin supplements
on HIV shedding in breast milk in HIV-infected lactating
women. Tanzanian lactating women (n=594) were randomized into four groups: placebo, multivitamin, vitamin A and
b-carotene, multivitamin with vitamin A plus b-carotene.
They found that mothers taking vitamin A and b-carotene
had higher detectable viral load than mothers not receiving
vitamin A. They concluded that supplementing HIV-infected
lactating mothers with vitamin A and b-carotene increases
the HIV viral load in the breast milk and, therefore, increases
the risk of mother-to-child transmission.85
The benefit of using formulas that contain multiple nutrients is that vitamins and minerals work in conjunction with
each other. Providing multiple micronutrients could influence
several mechanisms simultaneously, and the effect, instead
of being simply additive, becomes synergistic. One of the
main limitations of these trials of multiple supplementation
is that it is not possible to know which of the vitamins and
minerals had more activity, which is important information
to optimize formulas.
Recent studies suggest that microbial translocation
is a source of immune activation even in PLWH with a
Nutrition and Dietary Supplements 2016:8
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suppressed HIV viral load.108,109 Elevated plasma levels of
endotoxins, which are lipopolysaccharides derived from the
cell walls of gram-negative bacteria and a marker of microbial
translocation, are produced due to a defective intestinal
barrier and dysfunctional macrophage phagocytic clearance
of microbial products.110,111 The microbial products trigger
monocyte/macrophage activation that induces production
of proinflammatory cytokines and soluble CD14 (sCD14).42
Depletion of CD4+ Th17 cells in the GI wall, early in HIV
infection, reduces immunoprotection.112–115 The depletion
also disrupts the microbiota of the patient, which may lead
to greater dominance of potential pathogens, lower levels of
lactobacillus species, and increases mucosal inflammation.116
Modulation of gut microflora has been suggested as a safe
and promising treatment in HIV infection.117–119
Probiotics have been shown to have favorable effects
on alcoholic liver disease in clinical and experimental
animal research. 50–52,119 L. rhamnosus Gorbach–Goldin
is one of the most widely studied probiotic strains with
many well-documented benefits on several GI conditions
and diseases. 105,120 A limited number of studies using
probiotic supplementation have been conducted in HIV
infection;103–105,121–123 they have shown that probiotics were
safe and effective in reducing diarrhea, nausea, and stabilizing CD4+ T-cell numbers.124 L. rhamnosus Gorbach–Goldin
also reduced the duration and severity of diarrhea and
improved humoral immune responses.124,125 While most of
these studies have been limited by a small number of study
participants and/or short treatment duration,103–106 they support the notion that probiotics may provide benefits in HIV
infection, especially among patients with chronic alcohol
consumption.

Summary
In summary, the majority of the reviewed RCTs on nutritional
supplementation in PLWH were conducted before ART was
developed or initiated, underscoring the need for trials of
nutritional supplementation that include PLWH who are
receiving ART, to assist in the recuperation of the immune
response, maintaining adequate immune activation, reduce
inflammation, and reestablishing adequate microbiota, which
may be impaired by the long-term exposure to HIV and its
treatment.
The composition and doses of the formulas used prior and
after ART were diverse, but there was a convergence of the
investigators’ judgment on using multivitamin formulas with
a broader composition before ART was available or initiated.
An essential objective of the nutritional supplementation
of PLWH prior to their eligibility for ART was reversing
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nutritional deficiencies that were identified in previous
observational studies and delaying immune failure to prevent
secondary infections.
After the advent and initiation of ART, the objectives of
supplementation shifted to prevent the conditions that are
associated with the chronic exposure to ART and associated
with the aging of survivors, such as increased oxidative stress
and increased morbidity for liver, kidney, cardiovascular disease, and cancers, all major causes of non-HIV-related deaths
in PLWH.126 Our review confirms that nutritional supplementation with micronutrients and probiotics is immune stimulatory in both RCTs with ART-naive patients and in small trials
with patients on ART and controlled viral load.

Conclusion
The main aim in the treatment of PLWH is preserving and
enhancing the function of the immune system and reducing
or controlling viral load. Immune reconstitution, however,
does not always follow controlled viral load. While ART
is provided according to prescribed standards to diminish
HIV replication, the objectives of nutritional interventions
in conjunction with ART should be achieving immune
recovery, minimizing ART-related oxidative stress, preserving GI integrity, and preventing bacterial translocation and
malnutrition. The literature, however, is sparse on research
suggesting or demonstrating how to achieve these objectives
through supplementation.
Currently, as the global effort to curtail the HIV epidemic
is primarily directed toward broadening access to ART for
PLWH in developing countries, and HIV is becoming a chronically managed disease in developed countries, research on
HIV and nutrition should strive to evaluate the role of nutritional supplementation as a complementary therapy to ART.
Further studies are needed to concentrate on the development
of optimal nutrient formulas that foster immune recovery,
decrease the short- and long-term nutritional adverse effects
of ART, decrease bacterial translocation and immune activation, and prevent malnutrition. Trials with single nutrients
may elucidate the role of the individual nutrients in achieving these objectives and support the incorporation of these
nutrients into more complex formulas.
In PLWH, malnutrition inflicts an added immunesuppressive burden on the already immune-compromised
system. Therefore, developing interventions for the prevention of nutrient deficiencies, with or without receiving ART,
is still critical. Nutritional treatments should be individualized
according to the patient’s stage in the disease continuum,
the type of ART combination used, the patient’s nutritional

36

Powered by TCPDF (www.tcpdf.org)

submit your manuscript | www.dovepress.com

Dovepress

status such as undernutrition and obesity, environmental
exposure to opportunistic infections, and specific socioeconomic surroundings.127 Around the world, PLWH constitute
clusters of very diverse populations, surrounded by different
socioeconomic conditions that affect their access to treatment
and their nutritional status. Recommendations for nutritional
programs for PLWH need to be designed having in consideration this diversity.
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